Evidence as a HIV-1 self-defense vaccine of cyclic chimeric dodecapeptide warped from undecapeptidyl arch of extracellular loop 2 in both CCR5 and CXCR4

Biochemical and Biophysical Research Communications

Volumn 285, Issue 5, 2001, Pages 1309-1316

  Misumi, Shogo ^a   Takamune, Nobutoki ^a   Ido, Yasuhide ^a   Hayashi, Shinichiro ^a   Endo, Masafumi ^a   Mukai, Ryouzaburou ^b   Tachibana, Kuniomi ^c   Umeda, Mamoru ^c   Shoji, Shozo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Central Research Laboratory of Nissui Pharmaceutical Co Ltd   (Japan)

Author keywords

CCR5; Chemokine receptors; CXCR4; HIV 1 coreceptor based self defense vaccine

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYCLIC CHIMERIC DODECAPEPTIDYL MULTIPLE ANTIGEN PEPTIDE; DIPEPTIDE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; NEW DRUG; PENTAPEPTIDE; PEPTIDE; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBIOTIC SENSITIVITY; ANTIBODY PRODUCTION; ARTICLE; CALCIUM TRANSPORT; CHEMOTAXIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYBRIDOMA; IMMUNOGENICITY; INFECTION PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0034807088     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2001.5267     Document Type: Article

References (26)

1. AIDS vaccine development in primate models
2. Why do we not have an HIV vaccine and how can we make one?
3. Autoantibodies to CD4 in HIV type 1-exposed seronegative individuals
4. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro
5. Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity
6. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants
7. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4
8. Chemokine genes-beating the odds
9. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1
10. Identification of a major coreceptor for primary isolates of HIV-1
11. Identification of CXCR4 domains that support co-receptor and chemokine receptor functions
12. +cells is mediated by the chemokine receptor CC-CKR-5
13. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
14. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function
15. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5
16. Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity
17. A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1
18. Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line
19. Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using ccr5-expressing hela/cd4(+) cell clone 1-10 (magic-5)
20. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure
21. Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity
22. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
23. Relationship of HIV-1 envelope V2 and V3 sequences of the primary isolates to the viral phenotype
24. Interaction of chemokine receptor CCR5 with its ligands: Multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding
25. The second extracellular loop of CCR5 is the major determinant of ligand specificity